News >

Novel Strategies and Agents Emerge in AML Paradigm

Kristi Rosa
Published: Friday, Jan 24, 2020

Rebecca L. Olin, MD, MSCE, associate professor in the Department of Medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

Rebecca L. Olin, MD, MSCE

Although the success seen with FLT3 inhibitors may be the most exciting advancement made in recent years in the treatment of patients with acute myeloid leukemia (AML), said Rebecca L. Olin, MD, MSCE, recent data with venetoclax (Venclexta) and maintenance oral azacitidine (CC-486), both in older patients, are also changing practice.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication